These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 12847670

  • 1. Assessing the efficacy and safety of rheumatic disease treatments: obstacles and proposed solutions.
    Felson DT.
    Arthritis Rheum; 2003 Jul; 48(7):1781-7. PubMed ID: 12847670
    [No Abstract] [Full Text] [Related]

  • 2. Trials are short, disease long: measuring drug utility beyond clinical trials.
    Luggen ML.
    J Rheumatol; 2004 Feb; 31(2):205-6. PubMed ID: 14760785
    [No Abstract] [Full Text] [Related]

  • 3. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
    Mariette X.
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
    [No Abstract] [Full Text] [Related]

  • 4. [TNF-alpha antagonists in therapy of rheumatoid arthritis].
    Gross WL, Gause A.
    Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691
    [No Abstract] [Full Text] [Related]

  • 5. Primer: establishing a clinical trial unit - regulations and infrastructure.
    Fleischmann R.
    Nat Clin Pract Rheumatol; 2007 Apr; 3(4):234-9. PubMed ID: 17396109
    [Abstract] [Full Text] [Related]

  • 6. Are better endpoints and better design of clinical trials needed?
    Fransen J, van Riel PL.
    Best Pract Res Clin Rheumatol; 2004 Feb; 18(1):97-109. PubMed ID: 15123040
    [Abstract] [Full Text] [Related]

  • 7. [Fetal safety profile of drugs used in the treatment of inflammatory rheumatic diseases].
    Falcão S, Mourão AF, Pimentão JB, Branco JC.
    Acta Reumatol Port; 2007 Feb; 32(4):323-31. PubMed ID: 18159198
    [Abstract] [Full Text] [Related]

  • 8. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies.
    Woodworth TG, Furst DE, Strand V, Kempeni J, Fenner H, Lau CS, Miller F, Day R, Lipani J, Brooks P.
    J Rheumatol; 2001 May; 28(5):1163-9. PubMed ID: 11361207
    [Abstract] [Full Text] [Related]

  • 9. Optimisation of assessment for rheumatic diseases in clinical trials, observational studies and routine clinical care.
    Pincus T, Braun J, Kavanaugh A, Smolen JS.
    Clin Exp Rheumatol; 2014 May; 32(5 Suppl 85):S-1. PubMed ID: 25365080
    [No Abstract] [Full Text] [Related]

  • 10. The new British Society for Rheumatology disease modifying anti-rheumatic drugs guidelines.
    Deighton C, Gadsby K.
    Musculoskeletal Care; 2006 Sep; 4(3):174-81. PubMed ID: 17042028
    [No Abstract] [Full Text] [Related]

  • 11. Setting the research agenda for future clinical trials on the use of biologics in rheumatology.
    Silman A, Rudkin S, Walley T.
    Rheumatology (Oxford); 2011 Aug; 50(8):1356-7. PubMed ID: 21118870
    [No Abstract] [Full Text] [Related]

  • 12. Are individual patient trials (n-of-1 trials) in rheumatology worth the extra effort?
    Peloso PM.
    J Rheumatol; 2004 Jan; 31(1):8-11. PubMed ID: 14705210
    [No Abstract] [Full Text] [Related]

  • 13. Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index.
    Welch V, Singh G, Strand V, Fries J, Boers M, Ramey D, Day RO, Brooks P, Tugwell P, Clinch J, Kristjansson B.
    J Rheumatol; 2001 May; 28(5):1188-91. PubMed ID: 11361211
    [Abstract] [Full Text] [Related]

  • 14. [Evidence based medicine in rheumatology].
    Gause A, Raspe HH.
    Z Rheumatol; 2002 Oct; 61(5):516-8. PubMed ID: 12399877
    [No Abstract] [Full Text] [Related]

  • 15. Robin goodfellow.
    Rheumatology (Oxford); 2002 Sep; 41(9):1081. PubMed ID: 12209049
    [No Abstract] [Full Text] [Related]

  • 16. [Biological treatment of rheumatic diseases].
    Procházková L, Böhmová J, Soucek M.
    Vnitr Lek; 2006 Jun; 52(6):632-9. PubMed ID: 16871769
    [Abstract] [Full Text] [Related]

  • 17. The prevalence of underpowered randomized clinical trials in rheumatology.
    Keen HI, Pile K, Hill CL.
    J Rheumatol; 2005 Nov; 32(11):2083-8. PubMed ID: 16265683
    [Abstract] [Full Text] [Related]

  • 18. [Criteria of the effectiveness of antirheumatic agents in controlled clinical trials].
    Pavelka K.
    Ter Arkh; 1982 Nov; 54(6):106-9. PubMed ID: 7051392
    [No Abstract] [Full Text] [Related]

  • 19. Disease modifying antirheumatic drugs and pregnancy.
    Uhl K, Kennedy DL, Gilliland WR.
    J Rheumatol; 2004 Feb; 31(2):400-1; author reply 401-2. PubMed ID: 14760818
    [No Abstract] [Full Text] [Related]

  • 20. [Attitude of patient associations to clinical trials of new drugs].
    Tybkjaer HW, Witte L, Johannessen MB.
    Ugeskr Laeger; 2003 Apr 14; 165(16):1688-90. PubMed ID: 12756833
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.